Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Systemic lupus erythematosus
•
Complement system
How have you utilized commercial lab "SLE Monitoring Profiles" that include C3a and C4a components?
What are the limitations, usefulness, and caveats of this testing?
Related Questions
How do you interpret high C1q binding assay with otherwise normal C1q, C3, C4, CH50 in a patient with recurrent urticaria with positive ANA at high titer 1:1280, negative dsDNA, RNP, SM, normal CBC, CMP, UA, and UPCR.
What is your threshold to repeat a kidney biopsy in a patient with a history of lupus nephritis who is on maintenance therapy and develops subtle changes in urinary protein excretion or microscopic hematuria?
What is the clinical significance of a low titer RNP, negative Sm, but Sm/RNP that is very high titer?
How would you approach a young patient with bilateral lower extremity muscle weakness and positive anti-Smith, dsDNA, RNP, Raynaud’s, and pericardial effusion but normal muscle enzymes?
What is your approach to nephrology referral for patients with lupus nephritis?
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
What is your workup and treatment approach for cranial neuropathies in patients with lupus?
What is your approach to the diagnosis and management of optic chiasmitis in systemic lupus erythematosus?
Would you switch azathioprine to a different immunosuppressant if a controlled patient with SLE develops melanoma and/or non-melanoma skin cancer?
What is your approach to dosing and duration of rituximab for refractory lupus nephritis not responsive to cyclophosphamide or mycophenolate?